- Home
- MKFG vs IMAB Comparison
MKFG vs IMAB Comparison
Compare MKFG & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKFG
- IMAB
- Stock Information
- Founded
- MKFG 2013
- IMAB 2014
- Country
- MKFG United States
- IMAB United States
- Employees
- MKFG N/A
- IMAB N/A
- Industry
- MKFG Retail: Computer Software & Peripheral Equipment
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MKFG Technology
- IMAB Health Care
- Exchange
- MKFG Nasdaq
- IMAB Nasdaq
- Market Cap
- MKFG 79.2M
- IMAB 83.8M
- IPO Year
- MKFG N/A
- IMAB 2020
- Fundamental
- Price
- MKFG $3.71
- IMAB $0.95
- Analyst Decision
- MKFG Hold
- IMAB Strong Buy
- Analyst Count
- MKFG 2
- IMAB 3
- Target Price
- MKFG $5.00
- IMAB $8.00
- AVG Volume (30 Days)
- MKFG 113.7K
- IMAB 288.7K
- Earning Date
- MKFG 11-07-2024
- IMAB 08-28-2024
- Dividend Yield
- MKFG N/A
- IMAB N/A
- EPS Growth
- MKFG N/A
- IMAB N/A
- EPS
- MKFG N/A
- IMAB N/A
- Revenue
- MKFG $86,889,000.00
- IMAB $3,313,984.00
- Revenue This Year
- MKFG N/A
- IMAB N/A
- Revenue Next Year
- MKFG $9.45
- IMAB N/A
- P/E Ratio
- MKFG N/A
- IMAB N/A
- Revenue Growth
- MKFG N/A
- IMAB N/A
- 52 Week Low
- MKFG $1.57
- IMAB $0.90
- 52 Week High
- MKFG $8.80
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- MKFG 32.27
- IMAB 38.29
- Support Level
- MKFG $3.24
- IMAB $0.91
- Resistance Level
- MKFG $4.24
- IMAB $1.11
- Average True Range (ATR)
- MKFG 0.23
- IMAB 0.07
- MACD
- MKFG -0.03
- IMAB -0.00
- Stochastic Oscillator
- MKFG 32.28
- IMAB 13.01
About MKFG Markforged Holding Corporation
Markforged Holding Corp transforms manufacturing with 3D metal and continuous carbon fiber printers capable of producing parts tough enough for the factory floor. intuitive additive manufacturing platform for modern manufacturers, bringing the power and speed of agile software development to industrial manufacturing. Composed of hardware, software and materials working as a unified platform. It operates in industries such as Aerospace, Automotive, Consumer Packaged Goods, Education and Research, Electronics Manufacturing, Energy, Federal and Defense, Industrial Equipment. The company's geographical segments include the Americas; Europe, the Middle East, Africa; and Asia-Pacific. It derives maximum revenue from Americas.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).